| domain | evidence-based finding | suggested ontology identifiers/terms | evidence strength or limitation |
|---|---|---|---|
| Disease identity | Histiocytoid cardiomyopathy is a rare pediatric cardiac disease/tumor-like lesion characterized by conduction-system-like altered cardiomyocytes; historical literature notes fewer than 150 reported cases and current disease mapping includes MONDO:0010771. Historical synonyms include oncocytic cardiomyopathy, Purkinje cell hamartoma, and cardiac hamartoma (pqac-00000000, pqac-00000002) | MONDO:0010771; term-only: histiocytoid cardiomyopathy; term-only synonyms: oncocytic cardiomyopathy, Purkinje cell hamartoma, cardiac hamartoma | Moderate evidence from reviews/database mapping; rarity means estimates are literature-derived, not registry-based (pqac-00000000, pqac-00000002) |
| Core demographics / epidemiology | Predominantly affects infants, especially in the first year of life; many presentations are ventricular tachyarrhythmia or sudden cardiac death (pqac-00000000, pqac-00000001) | HPO term-only: Infantile onset; Ventricular tachycardia; Sudden cardiac death | Moderate evidence; no robust population incidence/prevalence study identified (pqac-00000000) |
| Phenotype: arrhythmia / sudden death | The hallmark presentation is malignant ventricular arrhythmia, often with sudden death or near-fatal events in infancy (pqac-00000000, pqac-00000001) | HPO term-only: Ventricular tachycardia; Arrhythmia; Sudden cardiac death | Strong clinical pattern across case literature/reviews, but frequency estimates remain imprecise (pqac-00000000) |
| Phenotype: hypertrophic cardiomyopathy | Hypertrophic cardiomyopathy is a major phenotype in NDUFB11-related disease and may overlap the histiocytoid spectrum; severe neonatal obstructive HCM was reported in a 2024 female case (pqac-00000009, pqac-00000010) | HPO term-only: Hypertrophic cardiomyopathy | Strong for NDUFB11-associated mitochondrial cardiomyopathy; exact fraction specifically within histiocytoid cardiomyopathy is uncertain (pqac-00000009, pqac-00000010) |
| Phenotype: ventricular noncompaction | Ventricular noncompaction/LV noncompaction is reported in the broader NDUFB11/mitochondrial cardiomyopathy spectrum and historical histiocytoid literature (pqac-00000001, pqac-00000010) | HPO term-only: Left ventricular noncompaction | Limited disease-specific evidence; association appears real but uncommon and based largely on case reports/reviews (pqac-00000001, pqac-00000010) |
| Phenotype: heart failure | Progressive heart failure can occur rapidly in neonatal-onset NDUFB11-associated disease; death by 48 hours to 3 months has been documented in recent reports (pqac-00000006, pqac-00000009) | HPO term-only: Heart failure | Strong for severe neonatal mitochondrial presentations; not all histiocytoid cases have the same course (pqac-00000006, pqac-00000009) |
| Phenotype: lactic acidosis | Lactic acidosis supports mitochondrial respiratory-chain dysfunction and was documented in recent NDUFB11 neonatal cases (pqac-00000006, pqac-00000010) | HPO term-only: Lactic acidosis; Elevated serum lactate | Strong in molecularly solved NDUFB11 cases; not universal across all historical histiocytoid reports (pqac-00000006, pqac-00000010) |
| Congenital anomalies / syndromic overlap | More than one-third of affected children have additional cardiac or extracardiac anomalies; overlap with microphthalmia with linear skin defects syndrome (MLS) has been reported in NDUFB11-related females (pqac-00000000, pqac-00000003) | HPO term-only: Multiple congenital anomalies; Microphthalmia; Linear skin defects | Moderate evidence; anomaly spectrum is heterogeneous and incompletely standardized (pqac-00000000, pqac-00000003) |
| Causal gene | NDUFB11 is the principal established disease gene linked to histiocytoid cardiomyopathy in current evidence resources and human studies (pqac-00000002, pqac-00000003) | HGNC symbol: NDUFB11; term-only: NADH:ubiquinone oxidoreductase subunit B11 | Strongest currently available gene-level evidence; other reported genes/variants remain secondary or candidate-level for this phenotype (pqac-00000002, pqac-00000003) |
| Inheritance | Inheritance is X-linked; affected males may present with severe neonatal disease, while heterozygous females may be asymptomatic or variably affected depending on X-inactivation (pqac-00000003, pqac-00000004, pqac-00000010) | term-only: X-linked inheritance | Strong human genetic evidence from segregation and de novo case reports (pqac-00000003, pqac-00000004, pqac-00000010) |
| Variable expressivity / X-inactivation | Skewed X-chromosome inactivation appears to modify penetrance and severity in females; recent work documented skewing ratios around 78:22 and 80:20 in carriers (pqac-00000004, pqac-00000005) | term-only: Skewed X-inactivation | Strong mechanistic modifier evidence in families studied, but based on small numbers (pqac-00000004, pqac-00000005) |
| Molecular mechanism | NDUFB11 encodes a mitochondrial respiratory-chain Complex I subunit; pathogenic variants impair canonical transcript/protein production, causing defective Complex I assembly/activity and mitochondrial cardiomyopathy (pqac-00000003, pqac-00000004, pqac-00000006) | GO term-only: mitochondrial respiratory chain complex I assembly; oxidative phosphorylation; mitochondrial electron transport, NADH to ubiquinone | Strong functional evidence from patient heart/skeletal muscle assays; pathway assignment is well supported (pqac-00000003, pqac-00000004, pqac-00000006) |
| Transcript/protein dysfunction | A 2023 NDUFB11 variant at the last nucleotide of exon 2 caused loss of the canonical short transcript, upregulation of a longer alternative transcript, absent/reduced NDUFB11 protein, and isolated Complex I deficiency (pqac-00000003, pqac-00000004, pqac-00000006) | Sequence Ontology term-only: splice-region/splice-altering variant; GO term-only: RNA splicing; protein-containing complex assembly | Strong disease-mechanism evidence, but derived from one deeply characterized family/proband (pqac-00000003, pqac-00000004, pqac-00000006) |
| Anatomy: organ / tissue | Primary sites are myocardium and endocardium, especially ventricles and atrioventricular/sinoatrial nodal regions, with conduction-system involvement central to pathobiology (pqac-00000000) | UBERON term-only: heart; cardiac ventricle myocardium; atrioventricular node; sinoatrial node; endocardium; myocardium | Moderate evidence from pathology reviews; exact lesion distribution varies case to case (pqac-00000000) |
| Cell type involvement | Lesional cells resemble modified myocytes of the cardiac conduction system / Purkinje-like cardiomyocytes (pqac-00000000) | CL term-only: cardiac muscle cell; Purkinje myocyte / conduction cardiomyocyte | Moderate evidence; precise modern cell-ontology mapping remains uncertain because historical pathology predates single-cell classification (pqac-00000000) |
| Subcellular localization | Mitochondria are central affected organelles; older pathology and modern mitochondrial genetics support abnormal mitochondrial accumulation/dysfunction in lesional cardiomyocytes (pqac-00000000, pqac-00000003) | GO Cellular Component term-only: mitochondrion; mitochondrial inner membrane; respiratory chain complex I | Moderate-to-strong evidence; ultrastructural detail is not uniformly available in recent accessible sources (pqac-00000000, pqac-00000003) |
| Diagnostic approach | Diagnosis is multimodal: ECG/rhythm monitoring for ventricular arrhythmia, echocardiography/cardiac MRI for cardiomyopathy morphology, metabolic testing for lactate/mitochondrial clues, and broad genomic testing (preferably WGS/WES or mitochondrial/cardiomyopathy panels that include NDUFB11); pathology remains definitive in some cases (pqac-00000009, pqac-00000010, pqac-00000003, pqac-00000006) | NCIT term-only: Electrocardiography; Echocardiography; Cardiac Magnetic Resonance Imaging; Whole Genome Sequencing; Whole Exome Sequencing; Gene Panel Sequencing; Pathologic Examination | Strong practical inference from recent case reports; no disease-specific consensus guideline identified (pqac-00000009, pqac-00000010, pqac-00000003, pqac-00000006) |
| Genetic testing implication | Recent evidence shows NDUFB11 may be missed by some commercial cardiomyopathy panels; rapid WGS can be critical in infantile cases (pqac-00000009) | NCIT term-only: Whole Genome Sequencing; Molecular Genetic Testing | Strong for at least some current panels; panel content is lab-dependent and changes over time (pqac-00000009) |
| Treatment categories | No approved disease-specific therapy exists. Management is case-based and may include antiarrhythmics/beta-blockade, catheter ablation or surgical lesion-directed treatment in selected arrhythmic cases, intensive heart-failure support, ECMO/VAD bridge, and heart transplantation; supportive mitochondrial care is empirical (recent disease-specific trials not found) (pqac-00000001, pqac-00000009) | NCIT term-only: Antiarrhythmic Therapy; Beta Adrenergic Receptor Blocking Agent Therapy; Catheter Ablation; Surgical Excision; Extracorporeal Membrane Oxygenation; Ventricular Assist Device; Heart Transplantation; Supportive Care | Weak-to-moderate evidence because treatment data are almost entirely case reports/series and extrapolation from pediatric mitochondrial cardiomyopathy practice (pqac-00000001, pqac-00000009) |
| Prognosis | Prognosis is often poor with highest mortality in infancy, particularly first-year presentations and severe neonatal mitochondrial disease (pqac-00000001, pqac-00000006, pqac-00000009) | HPO term-only: Sudden cardiac death; Infantile onset; Heart failure | Moderate evidence; no prospective natural-history cohort specific to histiocytoid cardiomyopathy identified (pqac-00000001, pqac-00000006, pqac-00000009) |
| Environmental / infectious factors | No reproducible environmental, lifestyle, occupational, or infectious causes are established; current evidence supports a primarily genetic/mitochondrial mechanism (pqac-00000003, pqac-00000008) | term-only: not established / no ontology assignment | Evidence gap rather than negative proof; rarity limits epidemiologic inference (pqac-00000003, pqac-00000008) |
| Major evidence gaps | No disease-specific clinical trials were found; limited epidemiology, no standardized diagnostic criteria, sparse quality-of-life data, no validated biomarkers beyond mitochondrial testing, and little disease-specific single-cell/spatial omics or model-organism work (pqac-00000001, pqac-00000002, pqac-00000003) | term-only: evidence gap; natural history study needed; biomarker development needed | Strong confidence that evidence is sparse because multiple searches yielded little disease-specific prospective/experimental literature (pqac-00000001, pqac-00000002, pqac-00000003) |


*Table: This table condenses the main evidence-based facts for histiocytoid cardiomyopathy, including core phenotype, genetics, mechanism, anatomy, diagnostics, treatment categories, and evidence limitations. It is designed for rapid knowledge-base curation with ontology term suggestions and citation-backed confidence notes.*